

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai,
Tan My Ward, Ho Chi Minh City, Viet Nam

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Quarter II 2026

Ho Chi Minh City, July 30, 2026



INDEX

	Page
REPORT OF THE BOARD OF DIRECTORS	2 - 3
CONSOLIDATED FINANCIAL STATEMENTS QUARTER II	
Consolidated Financial Position Report Quarter II	4 – 5
Consolidated business performance report Quarter II	6
Consolidated cash flow statement Quarter II	7
Notes to the Consolidated Financial Statements Quarter II	8 - 31

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors of American Vietnamese biotech inc (hereinafter referred to as "the Company") presents its Report and the Company's Consolidated Financial Statements for the Fourth Quarter.

Company Overview

American Vietnamese biotech inc was established and operated under the Business Registration Certificate of Joint Stock Company No. 3800237998, first registered on August 26, 2002, changed for the 24th time on August 17, 2025, issued by the Business Registration Office of the Department of Planning and Investment of Ho Chi Minh City.

Charter capital : 1.311.056.500.000 VND.

Stock code: AMV.

Number of shares: 131.105.650 shares.

Face value: 10.000 VND.

The Company's head office is located at 4th Floor, Phu Ma Duong Building , 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City.

The Company's business lines are medical equipment and medical testing chemicals.

Board of Directors and Management

Members of the Board of Directors and the Board of Management during the accounting period and up to the date of this report include:

Board of Directors

Mr. Nakatani Yoshitaka	Chairman of the Board
Mrs. Dang Nhi Nuong	Member
Mr. Le Khanh Nguyen	Member

Board of Directors

Mrs. Dang Nhi Nuong	Director
---------------------	----------

Legal representative

The legal representative of the Company during the accounting period and up to the time of this report is Ms. Dang Nhi Nuong - Director.

Responsibilities of the Board of Directors

The Board of Directors is responsible for preparing the consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated results of operations and consolidated cash flows of the Company during the accounting period. In preparing the consolidated financial statements for the fourth quarter, the Board of Directors must:

- Select suitable accounting policies and apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed. and all material discrepancies have been presented and explained in the Consolidated Financial Statements for the fourth quarter ;
- Prepare the consolidated financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business;

- Establish and implement an effective internal control system to minimize the risk of material misstatement due to fraud or error in the preparation and presentation of the quarterly consolidated financial statements. II .

The Board of Directors is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the financial position and performance of the Company and that the accounting records comply with the applicable accounting system. The Board of Directors is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and the statutory requirements relevant to the preparation and presentation of the Consolidated Financial Statements II .

The Board of Directors confirms that it has complied with the above requirements in preparing the Consolidated Financial Statements for the quarter II .

Approval of Consolidated Financial Statements

Board of Directors approves the quarterly consolidated financial statements II attached. The consolidated financial statements for the fourth quarter have fairly and fairly reflected the consolidated financial situation of the Company as of June 30, 2026 , as well as the consolidated business results for the quarter II and consolidated cash flows for the period ended on the same date, in accordance with accounting standards, Vietnamese Enterprise Accounting Regime and legal regulations related to the preparation and presentation of the Consolidated Financial Statements for the quarter II .

On behalf of the Board of Directors



Dang Nhi Nuong

Director

Ho Chi Minh City, July 30 , 2026

AMERICAN VIETNAMESE BIOTECH INC

4 F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

CONSOLIDATED FINANCIAL POSITION REPORT

As of June 30 , 2026

				Unit: VND
				01/01/2026
ASSET	Code	Note	30/06/2026	
A/ SHORT-TERM ASSETS	100		825.784.234.269	661.718.343.088
I/ Cash and cash equivalents	110	5.1	5.096.307.010	4.984.723.192
1. Cash	111		5.096.307.010	4.984.723.192
II/ Short-term financial investment	120		98.300.000	98.300.000
1. Held to maturity investment	123		98.300.000	98.300.000
III/ Short-term receivables	130		743.678.599.480	600.709.221.210
1. Short-term trade receivables	131	5.2	138.480.146.654	132.460.330.183
2. Short-term vendor advance	132	5.3	200.343.614.022	53.595.633.936
3. Short-term loan receivable	135		472.999.828.894	482.798.247.181
4. Other short-term receivables	136		(68.144.990.090)	(68.144.990.090)
IV/ Inventory	140	5.5	72.370.021.293	51.866.919.209
1. Inventory	141		72.370.021.293	51.866.919.209
VI/ Other short-term assets	160		4.541.006.486	4.059.179.477
1. Short-term prepaid expenses	161	5.6.1	81.591.768	235.635.831
2. Vat receivable	162		4.459.414.718	3.817.380.216
3. Taxes receivable from State Treasury	163	5.11	-	6.163.430
B/ LONG-TERM ASSETS	200		1.112.938.601.491	1.221.484.122.791
I/ Long-term receivables	210		125.919.600.000	187.642.000.000
1. Long-term loan receivable	215		125.919.600.000	187.642.000.000
II/ Fixed assets	220		261.577.045.723	272.804.916.889
1. Tangible fixed assets	221	5.7.1	151.903.015.472	163.457.614.566
- Original price	222		239.050.146.202	238.749.646.202
- Accumulated depreciation	223		(87.147.130.730)	(75.292.031.636)
2. Intangible fixed assets	227	5.7.2	109.674.030.251	109.347.302.323
- Original price	228		153.214.042.072	146.714.016.337
- Accumulated depreciation	229		(43.540.011.821)	(37.366.714.014)
IV/ Investment real estate	240		-	-
VI/ Long-term unfinished assets	250		19.901.837.232	26.445.368.646
1. Cost of unfinished basic construction	252		19.901.837.232	26.445.368.646
VII/ Long-term financial investment	260		701.999.442.777	730.720.256.523
1. Investment in joint ventures and associates	262		701.093.102.159	729.810.590.431
2. Investing in other entities	263		913.000.000	913.000.000
3. Provision for losses on long-term investments i	264		(6.659.382)	(3.333.908)
VIII/ Other long-term assets	270		3.540.675.759	3.871.580.733
1. Long-term prepaid expenses	271		3.431.509.960	3.752.490.770
	279		109.165.799	119.089.963
TOTAL ASSET	280		1.938.722.835.760	1.883.202.465.879

AMERICAN VIETNAMESE BIOTECH INC

4 F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

CONSOLIDATED FINANCIAL POSITION REPORT

As of June 30 , 2026

Unit: VND
01/01/2026

CAPITAL	Code	Note	30/06/2026	01/01/2026
C/ LIABILITIES PAYABLE	300		380.002.169.685	286.503.675.080
I/ Short-term debt	310		380.002.169.685	286.503.675.080
1. Short-term trade payables	311	5.9	62.649.948.446	20.725.343.083
2. Short-term advance payment buyer	312		536.205.818	324.126.900
3. Short-term taxes and amounts payable to s	314	5.11	2.276.197.886	2.915.106.176
4. Payable to workers	315		1.333.870.259	1.717.981.131
5. Short-term payable expenses	316	0	35.112.100.416	31.095.911.058
6. Short-term unearned revenue	319		2.328.353.671	2.972.558.744
7. Other short-term payables	320	5.10	115.139.397.362	77.126.552.161
8. Short-term loans and finance leases	321	5.12	160.626.095.827	149.626.095.827
II/ Long-term debt	330		-	-
D/ OWNER'S EQUITY	400		1.558.720.666.075	1.596.698.790.799
I Equity	410		1.558.720.666.075	1.596.698.790.799
1. Owner's equity	411		1.311.056.500.000	1.311.056.500.000
- Common shares with voting rights	411a		1.311.056.500.000	1.311.056.500.000
2. Capital surplus	412		(395.300.000)	(395.300.000)
3. Undistributed profit after tax	420		181.612.971.369	219.191.743.516
- Undistributed profit after tax	420a		219.191.743.516	291.829.173.766
- Undistributed profit this period	420b		(37.578.772.147)	(72.637.430.250)
4. Non-controlling interest	429		66.446.494.706	66.845.847.283
III Other funding sources and funds	430		-	-
TOTAL CAPITAL	440		1.938.722.835.760	1.883.202.465.879



Dang Nhi Nuong
Director

Ho Chi Minh City July 30 , 2026

Nguyen Thu Huyen
Chief Accountant

Tran Hang Nga
The chartist

AMERICAN VIETNAMESE BIOTECH INC

Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

CONSOLIDATED BUSINESS PERFORMANCE REPORT FOR THE SECOND QUARTER OF 2026

Unit: VND

INDICATORS	Code	Note	Quarter II		Cumulative figures from the beginning	
			This Year	Last Year	This Year	Last Year
1. Sales and service revenue	01	6,1	37.369.431.491	38.298.619.222	44.611.323.194	101.853.668.523
2. Revenue deductions	02	6,1	11.234.286	-	19.186.667	-
3. Net revenue from sales and services	10					
4. Cost of goods sold	11	6,2	37.358.197.205	38.298.619.222	44.592.136.527	101.853.668.523
5. Gross profit from sales and service	20		35.263.557.382	35.529.269.264	44.511.304.735	92.139.768.587
7. Financial revenue	22	6,3	2.094.639.823	2.769.349.958	80.831.792	9.713.899.936
8. Financial costs	23	6,4	575.548.207	539.567.576	1.203.437.173	951.192.571
9. Cost of sales	24		21.803.693.094	3.799.078.438	23.706.603.854	9.243.940.539
10. Business management costs	25	6,5	10.010.139.560	5.029.910.639	11.864.117.443	9.232.143.093
11. Net operating profit	26	6,6	109.265.601	140.326.263	189.009.011	282.102.526
12. Other income	30		6.133.262.878	34.715.442.974	10.966.729.425	39.183.146.667
13. Other costs	31	6,7	(1.957.152.661)	(37.553.551.936)	(4.269.670.754)	(40.251.719.020)
14. Other profits	32	6,8	(27.333.186.204)	(5.993.479)	781	163.086.200
15. Total accounting profit before tax	40		62.549.392	69.731.524	107.576.130	260.092.608
16. Current corporate income tax expense	50		(62.549.260)	(75.725.003)	(107.575.349)	(97.006.408)
18. Profit after corporate income tax	51	6,9	(27.395.735.464)	(37.629.276.939)	(37.955.319.428)	(40.348.725.428)
Net profit after tax of the parent company	60		-	-	-	(784.861.115)
After-tax profit of non-controlling shareholders	-		(27.395.735.464)	(37.629.276.939)	(37.955.319.428)	(39.563.864.313)
Basic Earnings Per Share	70		(27.316.140.365)	(39.401.235.353)	(37.578.772.147)	(39.049.852.550)
			(79.595.099)	1.771.958.414	(376.547.281)	(1.298.872.878)
			(226)	(301)	(287)	(298)

Net profit after tax of the parent company

After-tax profit of non-controlling shareholders

Basic Earnings Per Share


Tran Hang Nga
The chartist

Nguyen Thu Huyen
Chief Accountant


Dang Nhi Nuong
Director

Ho Chi Minh City July 30, 2026

AMERICAN VIETNAMESE BIOTECH INC

Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

CONSOLIDATED STATEMENT OF CASH FLOWS

(By indirect method)

Quarter II 2026

INDICATORS	Code	Unit: VND	
		From 01/01/2026 to 30/06/2026	From 01/01/2025 to 30/6/2025
I. Cash flow from operating activities			
1. <i>Profit before tax</i>	01	(37.955.319.428)	(40.348.725.428)
2. <i>Adjustments for the following items:</i>			
- Depreciation of fixed assets and investment real	02	18.028.396.901	16.076.993.545
- Provisions	03	-	27.477.026.152
- Profit and loss from investment activities	05	(1.203.437.173)	(598.992.571)
- Interest expense	06	11.864.117.443	9.232.143.093
<i>Profit from operations before changes in</i>			
3. <i>working capital</i>	08	(9.262.916.783)	11.838.444.791
- Increase, decrease receivables	09	(77.052.928.713)	291.455.996.231
- Increase, decrease inventory	10	(20.503.102.084)	(26.696.741.134)
- Increase, decrease payables	11	72.822.289.395	22.135.916.849
- Increase, decrease prepaid expenses	12	475.024.873	(162.838.606)
- Interest paid	14	(7.009.970.900)	(8.066.756.165)
- Corporate income tax paid	15	(560.249.143)	
Net cash flow from operating activities	20	(41.091.853.355)	290.504.021.966
II. Cash flow from investing activities			
Money spent on lending, buying debt instruments		-	(20.651.000.000)
1. other units	23	-	(20.651.000.000)
Proceeds from loan recovery, resale of debt		-	6.757.950.000
2. instruments other units	24	-	6.757.950.000
3. Money spent on investment in other entities	25	-	(320.004.500.000)
4. Proceeds from capital investment in other entities	26	29.000.000.000	40.900.000.000
5. Interest income, dividends and profits	27	1.203.437.173	951.192.571
Net cash flow from investing activities	30	30.203.437.173	(292.046.357.429)
III. Cash flow from financing activities			
1. Proceeds from borrowing	33	137.500.000.000	
2. Loan principal repayment	34	(126.500.000.000)	(1.499.000.000)
Net cash flow from financing activities	40	11.000.000.000	(1.499.000.000)
Net cash flow during the year	50	111.583.818	(3.041.335.463)
Cash and cash equivalents at the beginning			
of the	60	4.984.723.192	16.194.201.364
Cash and cash equivalents at the end of the			
year	70	5.096.307.010	13.152.865.901

Dang Nhi Nuong
Director

Ho Chi Minh City July 30, 2026


 Nguyen Thu Huyen
Chief Accountant


 Tran Hang Nga
The chartist

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

These notes are an integral part of and should be read in conjunction with the accompanying consolidated financial statements for the fourth quarter.

1. PERFORMANCE FEATURES

1.1 Form of capital ownership

American vietnamese biotech inc was established and operates under the Business Registration Certificate of Joint Stock Company No. 3800237998, first registered on August 26, 2002, changed for the 24rd time on August 17, 2025, issued by the Business Registration Office of the Department of Planning and Investment of Ho Chi Minh City .

Charter capital : 1.311.056.500.000 VND.

Stock code: AMV;

Number of shares: 131.105.650 shares;

Face value: 10.000 VND.

The Company's head office is located at 4th Floor, Phu Ma Duong Building , 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City.

1.2 Business Field

The Company's business lines are medical equipment and medical testing chemicals.

1.3 Business Line

Retail sale of drugs, medical equipment, cosmetics and hygiene products in specialized stores. Details: Trading in pharmaceuticals , buying and selling medical equipment, instruments and chemicals for medical testing; Production of medical, dental, orthopedic and rehabilitation equipment and instruments . Details: Production of medical testing instruments; Production of drugs, pharmaceutical chemicals and medicinal materials . Details: Production and trading of vaccines, medical biological products; Other medical actlties not elsewhere classified; Trading in real estate , land use rights of owners, users or lessees . Details: Real estate trading; Production of cosmetics, soaps, detergents, polishes and hygiene products; Agents , brokers, auctioneers . Details: Consignment agents; Production of plastic products; Actlties of asset holding companies. Details: Financial investment ; Other professional, scientific and technological actlties not elsewhere classified . Details: Technology transfer .

1.4 Normal production and business cycle

The Company's normal production and business cycle does not exceed 12 months.

1.5 Statement on Comparability of Information in Financial Statements

The corresponding figures of the previous period are comparable with the figures of the current period.

1.6 Directly owned subsidiaries , indirectly owned subsidiaries and associated companies are as follows:

Company	Place of establishment	Benefit ratio (%)	Voting rights	Main business actlties
Directly owned companies				
1. Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam	83.33	83.33	Wholesale of pharmaceuticals and medical instruments, wholesale of medical machinery and equipment

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**Quarter II 2026**

2. Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Cluster, Ba Che Commune, Quang Ninh Province, Vietnam	99	99	Manufacturing of drugs, medicinal chemicals and medicinal materials. Manufacture of ovens, furnaces and furnaces
3. Golab Uong Bi Testing Center Joint Stock Company	Group 4, Zone 4, Bai Chay Ward, Quang Ninh Province	98	98	General and Specialty Clinic
4. Song Hau New Technology Research and Application Joint Stock Company	Song Hau Industrial Park Phase 1, Chau Thanh Commune, Can Tho City, Vietnam	98	98	Production of ovens, furnaces and kilns
5. Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1 Phuc Thinh, Cau Buu, Kien Hung Ward, Hanoi City, Viet Nam	98	98	General, Specialty and Dental Clinic
6. Hoa Binh Clinic Joint Stock Company	1st Floor, No. 83 Cu Chinh Lan Street, Group 13, Hoa Binh Ward, Phu Tho Province, Vietnam	98	98	General, specialist and dental clinics
7. Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam	98	98	General, specialist and dental clinics
8. Gia Lam High-Tech Clinic Joint Stock Company	18 BT5 Phap Van - Tu Hiep Urban Area, Yen So Ward, Hanoi City, Vietnam	98	98	General, specialist and dental clinics
9. Can Tho Medicare Clinic Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Can Tho City, Vietnam	98	98	General, specialist and dental clinics
10. Hau Giang Medicare Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Area 4, Vi Thanh Ward, Can Tho City, Vietnam	98	98	General, specialist and dental clinics
11. Soc Trang Medicare Clinic Joint Stock Company	1st Floor Medicare Clinic Joint Stock Company, 438 Le Duan Street, Hamlet 4, Phu Loi Ward, Can Tho City, Vietnam	98	98	General, specialist and dental clinics
12. Golab Nga Bay Testing Center Joint Stock Company	No. 222, 30/4 Street, Area 5, Nga Bai Ward, Can Tho City	98	98	General, specialist and dental clinics
13. Leopard Solution Joint Stock Company	No. 34, Street 79, Hamlet Dinh, Cu Chi Commune, Ho Chi Minh City, Vietnam	75	75	Computer Programming Indirect Ownership Companies
Indirectly owned companies				
1. Famicare Thu Duc Joint Stock Company	28 Hien Vuong Street, Tang Nhon Phu Ward, Ho Chi Minh City, Vietnam	96.04	96.04	General, specialist and dental clinics
Investment in associates				
1. Huu Nghi Medicare Clinic Joint Stock Company	No. 179 Giai Phong Street, Bach Mai Ward, Hanoi City	49	49	General, specialist and dental clinics
2. Golab Ninh Binh Testing Center Joint Stock Company	1st Floor, House No. 140 Tue Tinh Street, Hoa Lu Ward, Ninh Binh	49	49	General, specialist and dental clinics

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**Quarter II 2026**

3. Golab Phap Van Testing Center Joint Stock Company	1st Floor, Lot BT 5, No. 18 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City	35	35	General, specialist and dental clinics
4. Famicare Phap Van Joint Stock Company	1st Floor, Lot BT 5, No. 17 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City	35	35	General, specialist and dental clinics
5. Golab Go Vap Testing Center Joint Stock Company	1st Floor, No. 178 Nguyen Thai Son, Hanh Thong Ward, Ho Chi Minh City	35	35	General, specialist and dental clinics
6. Nghe An Clinic Joint Stock Company	1st Floor, No. 68 Ho Tong Thoc Street, Block 13, Vinh Phu Ward, Nghe An	35	35	General, specialist and dental clinics
7. Ba Dinh Clinic Joint Stock Company	No. 37A Doc Phu San, De La Thanh Street, Lang Ward, Hanoi, Vietnam	35	35	General, specialist and dental clinics
8. Golab Bac Lieu Testing Center Joint Stock Company	Ground Floor, No. 210, Ba Trieu Street, Bac Lieu Ward, Ca Mau Province, Vietnam	35	35	General, specialist and dental clinics
9. Golab Binh Duong Testing Center Joint Stock Company	634 Binh Duong Boulevard, Zone 5, Phu Loi Ward, Ho Chi Minh City, Vietnam	35	35	General, specialist and dental clinics
10. Famicare Tuyen Quang Joint Stock Company	2nd Floor, No. 23, Hoa Lu Street, Group 01, Minh Xuan Ward, Tuyen Quang	35	35	General, specialist and dental clinics
11. Golab Vung Tau Testing Center Joint Stock Company	745 Vo Van Kiet Street, Tam Long Ward, Ho Chi Minh City, Vietnam	49	49	General, specialist and dental clinics
12. Golab Ha Giang Testing Center Joint Stock Company	1st Floor, No. 75, Nguyen Thai Hoc Street, Group 22, Ha Giang 2 Ward, Tuyen Quang	49	49	General, specialist and dental clinics
13. Golab Tien Giang Testing Center Joint Stock Company	368A, Phuoc Hoa Hamlet, Trung An Ward, Dong Thap Province, Vietnam	35	35	General, specialist and dental clinics

2. FISCAL YEAR, CURRENCY USED IN ACCOUNTING

The Company's fiscal year begins on January 1 and ends on December 31 of each year.

The currency used in accounting records is Vietnamese Dong (VND).

3. ACCOUNTING STANDARDS AND REGIMES APPLIED**3.1 Applicable accounting regime**

The Company applies the Corporate Accounting Regime issued under Circular No. 99/2025/TT-BTC promulgated by the Ministry of Finance, which replaces Circular No. 200/2014/TT-BTC and its related amendments and supplements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

The Company prepares consolidated financial statements in accordance with Circular No. 43/2026/TT-BTC amending Circular No. 202/2014/TT-BTC, which provides guidance on the preparation and presentation of consolidated financial statements

3.2 Statement on Compliance with Accounting Standards and Accounting Regime

The Company has applied Vietnamese Accounting Standards and documents guiding the Standards issued by the State. The consolidated financial statements are prepared and presented in accordance with all provisions of each standard, circular guiding the implementation of standards and the current applicable Accounting Regime.

3.3 Applicable accounting form

The company applies the general journal accounting method.

4. ACCOUNTING POLICIES APPLIED

4.1 Basis for preparing consolidated financial statements

Subsidiary

A subsidiary is an entity controlled by the parent company. Control exists when the parent company has the power, directly or indirectly, to govern the financial and operating policies of the subsidiary so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable or convertible are taken into account.

Consolidated basis

The Company's consolidated financial statements are prepared on the basis of consolidating the Company's separate financial statements and the financial statements of the Subsidiaries prepared for the fourth quarter of 2025 .

The financial statements of the subsidiaries are prepared using accounting policies that are consistent with those of the Company. Where necessary, adjustments are made to the financial statements of the subsidiaries to ensure consistency with the accounting policies used by the Company and its subsidiaries.

The results of operations of a subsidiary are included in the consolidated financial statements from the date of acquisition, which is the date on which the parent company takes control of the subsidiary. The results of operations of a subsidiary disposed of are included in the consolidated income statement up to the date of disposal.

The difference between the cost of the investment and the fair value of the identifiable net assets of the subsidiary at the acquisition date held by the parent company (when the parent company holds control of the subsidiary) is recorded as goodwill or gain from bargain purchase.

Intercompany balances, intra-group transactions, and unrealized gains/losses arising from these transactions are eliminated upon consolidation of the Financial Statements.

Non-controlling interests represent the portion of the Company's profits or losses and net assets not held by shareholders and are presented in a separate item on the Consolidated Balance Sheet and Consolidated Income Statement.

When the Company invests to increase its holding interest in a subsidiary, the difference between the cost of the additional investment and the book value of the net assets of the additional subsidiary is recorded directly in the item "Retained earnings" and is considered an equity transaction.

When the Company disposes part of its capital in a subsidiary:

- If after disposal, the Company still retains control: the result of disposal is recorded in the item "Undistributed profit after tax" of the Consolidated Balance Sheet.
- If after disposal, the Company loses control and the subsidiary becomes a joint venture or associate: the remaining investment is presented in the item "Investment in joint ventures and associates" on the Consolidated Financial Statements using the equity method and the result of disposal is recorded in the Consolidated Income Statement.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

- If after the dlestant, the Company loses control and the subsidiary becomes a normal investment: the remaining investment is presented under the cost method and the result of the dlestant is recognized in the Consolidated Statement of Business Performance.

In case a subsidiary raises additional capital contributions from owners, if the additional capital contribution ratio of the parties does not correspond to the current ratio, the difference between the additional capital contribution of the Company and the increased ownership in the net assets of the subsidiary is recorded in the item "Undistributed profit after tax" on the Consolidated Balance Sheet.

4.2 Cash and cash equvalents

Cash includes cash, demand and term bank deposits, cash in transit, monetary gold. Cash equvalents are short-term investments with a maturity of no more than 3 months from the date of investment that can be easily converted into a known amount of cash and are subject to no risk of change in value at the reporting date.

4.3 Accounts Recelable

Accounts recelable are stated at carrying amount less allowance for doubtful debts.

The classification of recelables as trade recelables, internal recelables and other recelables is carried out according to the following principles:

- Trade recelables reflect commercial recelables arising from purchase-sale transactions between the Company and buyers who are independent entities of the Company, including recelables from export sales entrusted to other entities.
- Internal recelables reflect recelables from affiliated units without legal entity status that are dependent on accounting.
- Other recelables reflect non-commercial recelables not related to purchase and sale transactions.

Provision for doubtful debts is made for each doubtful debt based on the age of overdue debts or the expected level of loss that may occur, specifically as follows:

- For overdue recelables:
 - 30% of the value for overdue recelables from more than 6 months to less than 1 year.
 - 50% of the value for recelables overdue from 1 year to less than 2 years.
 - 70% of the value for recelables overdue from 2 years to less than 3 years.
 - 100% of the value for recelables overdue for 3 years or more.
- For recelables that are not overdue but are unlikely to be recovered: establish provisions based on expected loss level.

Increases and decreases in the balance of the provision for doubtful debts that must be set up at the end of the accounting period are recorded in business administration expenses.

4.4 Inventory

Inventories are stated at the lower of cost and net realizable value.

The cost of inventories includes purchase costs, processing costs and other directly relevant costs incurred in bringing the inventories to their present location and condition.

Net realizable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

Inventories are valued using the weighted average method and accounted for using the perpetual inventory method.

Provision for inventory devaluation is established for each inventory item whose original cost is greater than its net realizable value. Increases or decreases in the balance of provision for inventory devaluation that must be established at the end of the accounting period are recorded in cost of goods sold.

4.5 Fixed assets and depreciation of fixed assets

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

Tangible fixed assets and intangible fixed assets are recorded at original cost. During use, tangible fixed assets and intangible fixed assets are recorded at original cost, accumulated depreciation and residual value.

original cost of fixed assets includes all costs that the Company must spend to acquire fixed assets up to the time the asset is ready for use. Costs incurred after initial recognition are only recorded as an increase in the original cost of fixed assets if these costs certainly increase future economic benefits from the use of that asset . Costs incurred that do not satisfy the above conditions are recorded as production and business costs in the period.

fixed assets are sold or liquidated, their cost and accumulated depreciation are written off and any gain or loss arising from their disposal is recognized in income or expenses in the period.

Depreciation is calculated using the straight-line method. based on the estimated useful life in accordance with the provisions of Circular 45/2013/TT-BTC dated April 25, 2013, amended and supplemented according to the provisions of Circular 147/2016/TT-BTC dated October 13, 2016 and Circular 28 /2017/TT-BTC dated April 12, 2017 on guidance on the management, use and depreciation of fixed assets.

4.6 Prepaid expenses

Prepaid expenses include short-term prepaid expenses or long-term prepaid expenses on the balance sheet and are allocated over the period of prepayment of the expenses corresponding to the economic benefits generated from these expenses.

4.7 Accounts Payable and Accrued Expenses

Liabilities and accruals are recognized for amounts to be paid in the future for goods and services received. Accruals are recognized based on reasonable estimates of the amounts to be paid.

The classification of payables as trade payables, accrued expenses, internal payables and other payables is carried out according to the following principles:

- Trade payables reflect commercial payables arising from transactions of purchasing goods, services, assets and the seller is an independent entity of the Company, including payables when importing through consignees.
- Payable expenses reflect amounts payable for goods and services received from sellers or provided to buyers but not yet paid due to lack of invoices or insufficient accounting records and documents, and amounts payable to employees for leave wages, production and business expenses that must be accrued in advance.
- Internal payables reflect payables between a parent unit and a subordinate unit without legal entity status that is dependent on accounting.
- Other payables reflect non-commercial payables not related to the purchase, sale or provision of goods and services.

4.8 Loans and financial lease liabilities

Loans are tracked by each lender, each loan agreement and the repayment period of the loans. In case of loans in foreign currency, detailed tracking is performed by original currency.

4.9 Borrowing costs

Borrowing costs include interest and other costs incurred in connection with borrowing.

Borrowing costs are recognized as expenses when incurred. Where borrowing costs are directly related to the construction or production of an asset that takes a substantial period of time (over 12 months) to get ready for its intended use or sale, these borrowing costs are capitalized. For loans specifically used to build fixed assets or investment properties, interest is capitalized even if the construction period is less than 12 months. Income from temporary investment of loans is recorded as a reduction in the original cost of the related assets.

For general borrowings used for the purpose of investment in construction or production of unfinished assets, the capitalized borrowing costs are determined according to the capitalization rate for the weighted average cumulative costs incurred for investment in basic construction or production of that asset. The capitalization rate is calculated

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

according to the weighted average interest rate of the outstanding borrowings during the period, except for separate borrowings serving the purpose of forming a specific asset.

4.10 Equity

equity is recorded according to the actual capital contributed by shareholders.

4.11 Profit Distribution

Profit after corporate income tax is distributed to shareholders after setting aside funds according to the Company's Charter as well as legal regulations and approved by the General Meeting of Shareholders.

4.12 Revenue and income

Sales revenue

Sales revenue is recognized when all of the following conditions are met:

- The significant risks and rewards of ownership of the product or goods have been transferred to the buyer;
- The Company no longer holds the right to manage the goods as the owner of the goods or the right to control the goods;
- Revenue is measured with relative certainty;
- The Company has obtained or will obtain economic benefits associated with the sale transaction;
- Identify the costs associated with a sales transaction.

Service revenue

Revenue from rendering of services is recognised when the outcome of the transaction can be estimated reliably. Where the provision of services is related to several periods, revenue is recognised in the period according to the results of the work completed at the date of preparation of the Consolidated Balance Sheet of that period. The outcome of the service provision transaction is determined when the following conditions are satisfied:

- Revenue is measured with relative certainty;
- It is possible to obtain economic benefits from the transaction of providing that service;
- Determine the portion of work completed as of the date of the Consolidated Balance Sheet;
- Identify the costs incurred for the transaction and the costs to complete the transaction to provide that service.

The portion of service work completed is determined by the method of assessing completed work.

Financial revenue

Revenue arising from interest, royalties, dividends, profits shared and other financial revenue is recorded when both (2) of the following conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the entity;
- Revenue is determined with relative certainty.

Dividends and profits distributed are recorded when the Company is entitled to receive dividends or profits from capital contributions. Dividends received in shares are only tracked by the number of shares increased, not recording the value of shares received, not recording financial activity revenue.

Interest is recognized on an accrual basis, determined on the deposit account balance and the actual interest rate for each period.

4.13 Corporate income tax

Current income tax

Current income tax is the tax that is calculated on taxable income. Taxable income differs from accounting profit due to adjustments for temporary differences between tax and accounting, non-deductible expenses as well as adjustments for non-taxable income and losses carried forward.

4.14 Stakeholders

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**Quarter II 2026**

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. The Company's related parties include:

- Enterprises that directly or indirectly through one or more intermediaries, control or are controlled by, or are under common control with, the Company, including parent companies, subsidiaries and affiliates;
- Individuals who directly or indirectly hold voting rights of the Company and have significant influence over the Company, key management personnel of the Company, close family members of these individuals;
- Enterprises in which the above individuals directly or indirectly hold a significant portion of voting rights or have significant influence on the Company.

5. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE CONSOLIDATED BALANCE SHEET**5.1 Cash and cash equivalents**

	30/6/2026	01/01/2026
Cash on hand	4.589.193.702	2.322.261.587
Bank demand deposits	507.113.308	2.662.461.605
Total	5.096.307.010	4.984.723.192

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.2 Short-term trade receivables

	Value VND	30/06/2026 Provision VND	Value VND	01/01/2026 Provision VND
Other parties	138.480.146.654	(294.325.128)	132.460.330.183	(294.325.128)
Lou Investment Joint Stock Company	11.381.000.000	-	26.114.352.706	-
Golab An Giang Laboratory Center Joint Stock Company	1.120.000.000	-	5.000.000	-
Golab Kon Tum Laboratory Center Joint Stock Company	1.500.330.000	-	1.500.330.000	-
G7 High Technology Joint Stock Company	2.226.000.000	-	2.226.000.000	-
Sara Viet Nam Joint stock company	3.927.000.000	-	3.927.000.000	-
Phu Tho Province Obstetrics and Pediatrics Hospital	726.083.264	-	392.157.788	-
Hanoi Children's Hospital	1.021.029.200	-	1.079.342.650	-
Trung My Tay General Hospital"	544.265.898	-	544.265.898	-
Tan Son Regional Medical Cente	283.774.000	-	852.707.200	-
Nhat Medical Equipment Co., Ltd,	705.000.000	-	9.323.000.000	-
Golab Go Vap Laboratory Center Joint Stock Company	3.715.660.000	-	3.715.660.000	-
Golab Bac Lieu Laboratory Center Joint Stock Company	2.268.660.000	-	2.268.660.000	-
Golab Hai Duong Laboratory Center Joint Stock Company	2.060.000.000	-	2.065.000.000	-
Golab Ha Tinh Laboratory Center Joint Stock Company	1.149.807.175	-	1.154.807.175	-
Golab Bien Hoa Laboratory Center Joint Stock Company	5.000.000.000	-	5.600.660.000	-
Golab Hai Phong Laboratory Center Joint Stock Company	1.120.000.000	-	1.125.000.000	-
Golab Testing Center Joint Stock Company District 5	1.120.000.000	-	1.125.000.000	-
Golab Thai Binh Laboratory Center Joint Stock Company	1.120.000.000	-	1.125.000.000	-
Golab Thanh Hoa Laboratory Center Joint Stock Company	1.393.000.000	-	1.125.000.000	-
Golab Binh Dinh Laboratory Center Joint Stock Company	1.125.000.000	-	1.125.000.000	-
Golab Quang Binh Laboratory Center Joint Stock Company	1.120.000.000	-	1.125.000.000	-
Golab Phap Van Laboratory Center Joint Stock Company	1.125.000.000	-	1.125.000.000	-
Golab Ninh Binh Laboratory Center Joint Stock Company	1.156.172.300	-	1.161.172.300	-

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**Quarter II 2026**

Nghe An General Clinic Joint Stock Company	1.957.330.000	-	1.962.330.000	-
Ba Dinh General Clinic Joint Stock Company	2.073.750.000	-	2.073.750.000	-
Golab Da Nang Laboratory Center Joint Stock Company	3.525.440.000	-	3.525.440.000	-
Golab Quang Tri Laboratory Center Joint Stock Company	1.920.440.000	-	1.920.440.000	-
Golab Tuyen Quang Laboratory Center Joint Stock Company	1.120.000.000	-	1.125.000.000	-
Golab Quang Ngai Laboratory Center Joint Stock Company	2.920.330.000	-	2.925.330.000	-
Golab Yen Bai Laboratory Center Joint Stock Company	2.548.000.000	-	3.397.660.000	-
Golab Dong Thap Laboratory Center Joint Stock Company	3.346.000.000	-	5.000.000	-
Golab Hue Laboratory Center Joint Stock Company	3.045.000.000	-	3.045.000.000	-
Golab Binh Phuoc Laboratory Center Joint Stock Company	1.926.300.000	-	1.926.300.000	-
Golab Khanh Hoa Laboratory Center Joint Stock Company	3.193.750.000	-	3.198.750.000	-
Golab Cao Bang Laboratory Center Joint Stock Company	2.226.000.000	-	2.226.000.000	-
Golab Lam Dong Laboratory Center Joint Stock Company	4.299.750.000	-	4.299.750.000	-
Hoa Binh Agricultural Machinery Investment Joint Stock Company	13.377.000.000	-	13.377.000.000	-
Vinam Joint Stock Company	6.258.000.000	-	-	-
Golab Quang Nam Laboratory Center Joint Stock Company	1.326.000.000	-	1.331.000.000	-
Golab Vinh Yen Laboratory Center Joint Stock Company	1.252.791.156	-	1.257.791.156	-
Other customers	35.256.483.661	(294.325.128)	15.058.673.310	(294.325.128)
Total	138.480.146.654	(294.325.128)	132.460.330.183	(294.325.128)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.3 Short-term vendor advance

	30/06/2026		01/01/2026	
	Value VND	Provision VND	Value VND	Provision VND
Other parties	200.343.614.022	-	53.595.633.936	-
Japan Kanpeki Joint Stock Company	61.046.793.289	-	9.004.623.955	-
High-Tech Medical Environment Company Limited	27.957.000.000	-	3.430.000.000	-
Can Tho High-Tech Investment Joint Stock Company	35.076.500.000	-	13.136.500.000	-
Lou Investment Joint Stock Company	63.597.260.000	-	7.719.000.000	-
Can Tho Laboratory and Environment Center Joint Stock Company	5.470.500.000	-	5.470.500.000	-
Hoa Binh Agricultural Machinery Investment Joint Stock Company	-	-	10.472.170.000	-
Other suppliers	7.195.560.733	-	4.362.839.981	-
Total	200.343.614.022	-	53.595.633.936	-



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.4 Other receivables

5.4.1 Other short-term receivables

	30/06/2026		01/01/2026	
	Value VND	Provision VND	Value VND	Provision VND
Deposits and Guarantees	3.612.608.685	-	937.864.916	-
Loan	-	-	-	-
Advances to Employees and Other Parti	4.709.324.100	-	180.122.844	-
Hà Long Tokyo Environment and Health High Technology Joint Stock Company	-	-	5.842.050.000	-
G7 High-Tech Joint Stock Company	-	-	4.000.000.000	-
Can Tho High-Tech Investment Joint Stock Company	16.312.000.000	(12.168.990.767)	10.120.000.000	(12.168.990.767)
Phu Tho Obstetrics and Pediatrics Hospital	15.069.901.746	-	23.500.000.000	-
Bai Chay Kyoto Clinic Joint Stock Company	1.752.831.192	-	-	-
High-Tech Medical Environment Company Limited	64.160.000.000	(4.336.000.000)	54.232.000.000	(4.336.000.000)
Hoa Binh Agricultural Machinery Investment Joint Stock Company	69.163.750.000	(25.019.000.000)	69.663.750.000	(25.019.000.000)
Can Tho Laboratory and Environment Center Joint Stock Company	9.400.000.000	(7.993.148.000)	9.400.000.000	(7.993.148.000)
Ha Long Osaka High-Tech Equipment Manufacturing Joint Stock Company	-	-	3.601.000.000	-
Nhat Medical Equipment Company Limited	34.403.000.000	-	34.403.000.000	-
Lou Investment Joint Stock Company	25.226.000.000	(7.687.800.000)	25.226.000.000	(7.687.800.000)
Sara Hospital Investment Joint Stock Company	16.515.000.000	(9.940.614.195)	17.055.000.000	(9.940.614.195)
Sara Viet Nam Joint Stock Company	20.651.000.000	-	20.651.000.000	-
Other Receivables	192.024.413.171	(705.112.000)	203.986.459.421	(705.112.000)
Total	472.999.828.894	(67.850.664.962)	482.798.247.181	(67.850.664.962)

5.4.2 Other long-term receivables

	30/06/2026		01/01/2026	
	Value VND	Provision VND	Value VND	Provision VND
Sara Vung Tau Joint Stock Company	-	-	61.717.000.000	-
Phu Tho Obstetrics and Pediatrics Hospital	125.801.600.000	-	125.794.000.000	-
	-	-	-	-
Other long-term receivables	118.000.000	-	131.000.000	-
	-	-	-	-
Total	125.919.600.000	-	187.642.000.000	-

(i) Receivables under business cooperation contracts:

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

- Investment cooperation contract No. 11.12/2020/SRVT-BVVM dated December 11, 2020 between Viet My Hospital Investment Joint Stock Company and Sara Vung Tau Joint Stock Company on the construction of a centralized medical waste treatment area using negatle pressure - smokeless incineration technology.

5.5 Inventor

	30/06/2026		01/01/2026	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
Raw materials	1.624.029.196	-	1.561.821.918	-
Tools and instruments	294.964.041	-	259.206.437	-
Final goods	70.451.028.056	-	50.045.890.854	-
Total	72.370.021.293	-	51.866.919.209	-

5.6 Prepaid expenses

5.6.1. Short-term prepaid expenses

	30/06/2026	01/01/2026
	VND	VND
Tools and Supplies	39.987.124	86.325.138
Other Short-term Prepaid Expenses	41.604.644	149.310.693
Total	81.591.768	235.635.831

5.6.2. Long-term prepaid expenses

	30/06/2026	01/01/2026
	VND	VND
Other Long-term Prepaid Expenses	3.431.509.960	3.752.490.770
Total	3.431.509.960	3.752.490.770

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.7	Increase or decrease in fixed assets				
5.7.1	Increase or decrease in tangible fixed assets				
		Buildings and structures VND	Machinery and Equipment VND	Transport and Transmission Vehicles VND	Total VND
Original cost					
Balance as of 01/01/2026	10.894.525.377	227.610.580.825	244.540.000	238.749.646.202	
Purchase in year	-	300.500.000	-	300.500.000	
Disposal, sale	-	-	-	-	
Balance as of 30/06/2026	10.894.525.377	227.911.080.825	244.540.000	239.050.146.202	
Depreciation valu					
Depreciation in year	5.429.064.099	69.618.427.537	244.540.000	75.292.031.636	
	330.545.658	10.813.786.770	-	11.144.332.428	
Disposal, sale	-	-	-	-	
Reclassified	-	-	-	-	
	5.759.609.757	81.142.980.973	244.540.000	87.147.130.730	
Net Book Value					
Balance as of 01/01/2026	5.465.461.278	157.992.153.288	-	163.457.614.566	
Balance as of 30/06/2026	5.134.915.620	146.768.099.852	-	151.903.015.472	

5.7.2 Increase or decrease of intangible fixed assets

	Software Program VND	Total VND
ORIGINAL COST		
Balance as of 01/01/2026	146.714.016.337	146.714.016.337
Purchase in year	-	-
	6.500.025.735	6.500.025.735
Balance as of 30/06/2026	<u>153.214.042.072</u>	<u>153.214.042.072</u>
DEPRECIATION VALUE		
Balance as of 01/01/2026	37.366.714.014	37.366.714.014
Depreciation in year	6.173.297.807	6.173.297.807
Balance as of 30/06/2026	<u>43.540.011.821</u>	<u>43.540.011.821</u>
NET BOOK VALUE		
Balance as of 01/01/2026	109.347.302.323	109.347.302.323
Balance as of 30/06/2026	<u>109.674.030.251</u>	<u>109.674.030.251</u>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.8 Cost of unfinished basic construction

	30/06/2026	01/01/2026
	VND	VND
Purchases	19.901.837.232	26.445.368.646
Total	19.901.837.232	26.445.368.646

5.9 Short-term trade payables

	30/06/2026	01/01/2026
	VND	VND
Hong Anh Technique Company Limited	5.121.859.377	5.121.859.377
Japan Medical Equipment Co., Ltd.	6.426.000.000	-
JWB Co.,Ltd	298.643.120	-
Aiko International Group Joint Stock Company	23.100.000.000	4.725.000.000
Japan Kanpeki Joint Stock Company	108.527.875	226.953.811
Vinam Joint Stock Company	1.186.500.000	-
G7 High-Tech Joint Stock Company	-	288.750.000
Viet My Hospital Investment Joint Stock Company	273.000.000	329.080.000
Golab Ha Tinh Testing Center Joint Stock Company	2.940.000.000	-
Other Suppliers	23.195.418.074	10.033.699.895
Total	62.649.948.446	20.725.343.083

5.10 Other short-term payables

	30/06/2026	01/01/2026
	VND	VND
Social insurance, health insurance, unemployment insurance, union funds	243.740.429	82.730.300
Dividends and other payables	76.862.966.862	76.731.921.861
Other payables	38.032.690.071	311.900.000
Total	115.139.397.362	77.126.552.161

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.11 Taxes and receivables, payable to the State

Taxes and amounts payable to th	Receivables at the beginning of the year	Amount payable at the beginning of the year	Amount payable during the year	Amount actually paid during the year	Year-end receivables	Amount payable at year- end
	VND	VND	VND	VND	VND	VND
Value Added Tax on Domestic Sale	-	656.930.109	473.782.058	580.878.211	-	549.833.956
Value Added Tax on Imported Goods	-	-	12.400.302	12.400.302	-	-
Corporate Income Tax	-	2.088.809.445	-	560.249.143	-	1.528.560.302
Personal Income Tax	2	169.366.622	217.150.235	188.713.227	-	197.803.628
Fees, charges and other accounts	6.163.428	-	12.326.856	6.163.428	-	-
	-	-	-	-	-	-
Total	6.163.430	2.915.106.176	715.659.451	1.348.404.311	-	2.276.197.886

5.12 Loans and financial leases

	30/06/2026		01/01/2026	
	VND	Value Amount available for debt repayment VND	VND	Value Amount available for debt repayment VND
Short-term loans	160.626.095.827	160.626.095.827	23.126.095.827	149.626.095.827
Short-term loans	160.626.095.827	160.626.095.827	-	126.500.000.000
Short-term Ordinary Bonds	137.500.000.000	137.500.000.000	126.500.000.000	126.500.000.000
Ban Viet Commercial Joint Stock Bank - Hanoi Branch	23.126.095.827	23.126.095.827	23.126.095.827	23.126.095.827
Total	160.626.095.827	160.626.095.827	137.500.000.000	149.626.095.827

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

5.13 Equity Equity Fluctuation Reconciliation Table

	Owner's investment capita VND	Share premium VND	Retained earnings VND	Non-controlling interests VND	Total VND
Beginning balance of the	1.311.056.500.000	(395.300.000)	291.829.173.766	70.219.436.558	1.672.709.810.324
Profit in the previous	-	-	-	-	-
Distribution of dividends and profits	-	-	(72.637.430.250)	(1.858.989.756)	(74.496.420.006)
Increase/decrease resulting from	-	-	-	(347.129.374)	(347.129.374)
Ending balance of the	1.311.056.500.000	(395.300.000)	219.191.743.516	(1.167.470.145)	(1.167.470.145)
Beginning balance of the	1.311.056.500.000	(395.300.000)	219.191.743.516	66.845.847.283	1.596.698.790.799
Loss this year	-	-	(37.578.772.147)	(376.547.281)	(37.955.319.428)
Distribution of dividends and profits	-	-	-	-	-
Different increases and decreases	-	-	-	(22.805.296)	(22.805.296)
Ending balance of the	1.311.056.500.000	(395.300.000)	181.612.971.369	66.446.494.706	1.558.720.666.075

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

Share

	30/06/2026 <i>Share</i>	01/01/2026 <i>Share</i>
Number of shares registered to issue	131.105.650	131.105.650
Number of shares sold to the public	131.105.650	131.105.650
Common shares	131.105.650	131.105.650
Number of outstanding shares	131.105.650	131.105.650
	-	-
Par value of outstanding shares (VND/Share)	10.000	10.000

6. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE CONSOLIDATED STATEMENT OF INCOME

6.1 Sales and service revenue

	Quarter II 2026 <i>VND</i>	Quarter II 2025 <i>VND</i>
Sales and service revenue	37.369.431.491	38.298.619.222
	<u>37.369.431.491</u>	<u>38.298.619.222</u>

6.2 Cost of goods sold

	Quarter II 2026 <i>VND</i>	Quarter II 2025 <i>VND</i>
Cost of goods sold and services rendered	35.263.557.382	35.529.269.264
Cost of other operations		
Total	<u>35.263.557.382</u>	<u>35.529.269.264</u>

6.3 Financial revenue

	Quarter II 2026 <i>VND</i>	Quarter II 2025 <i>VND</i>
Interest on deposits and loans	575.548.207	539.567.576
Total	<u>575.548.207</u>	<u>539.567.576</u>

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

6.4 Financial costs

	Quarter II 2026 VND	Quarter II 2025 VND
Provision for impairment of trading securities and investment losses	21.803.693.094	3.799.078.438
	-	-
Total	21.803.693.094	3.799.078.438

6.5 Cost of sales

	Quarter II 2026 VND	Quarter II 2025 VND
Other cash expenses	109.265.601	140.326.263
	-	-
Total	109.265.601	140.326.263

6.6 Business management costs

	Quarter II 2026 VND	Quarter II 2025 VND
Employee expenses	2.106.449.325	2.357.488.978
	703.999.526	-
Other expenses"	3.322.814.027	32.357.953.996
	-	-
Total	6.133.262.878	34.715.442.974

6.7 Other income

	Quarter II 2026 VND	Quarter II 2025 VND
Other amounts	132	(5.993.479)
	-	-
Total	132	(5.993.479)
Other costs		

6.8 Other amounts

	Quarter II 2026 VND	Quarter II 2025 VND
	62.549.392	69.731.524
	-	-
Total	62.549.392	69.731.524

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

7. FINANCIAL INSTRUMENTS

Types of financial instruments of the Company

The Company has financial assets such as cash and cash equivalents, trade receivables, other receivables, listed and unlisted financial instruments. The Company's financial liabilities mainly include trade payables, loans and borrowings, accrued expenses and other payables. The main purpose of these financial liabilities is to mobilize financial resources for the Company's operations.

The Company is exposed to market risk, credit risk and liquidity risk. The Company has not hedged these risks due to the lack of a market to trade financial instruments.

The Board of Directors reviews and agrees to apply management policies for the above risks as follows:

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk includes: interest rate risk, commodity price risk and other price risks, such as equity price risk.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of market interest rates. The Company's exposure to market risk from changes in interest rates relates primarily to the Company's cash and borrowings.

The Company manages interest rate risk by analyzing the competitive situation in the market to obtain interest rates favorable to the Company's purposes.

Commodity price risk

The Company is exposed to commodity and service price risks due to the purchase of goods and services for the Company's business operations. The Company manages commodity price risks by closely monitoring relevant market information and situations, and by organizing bidding for large value purchase contracts with contractors and suppliers on a fixed unit price or fixed lump sum price basis.

Stock price risk

The securities held by the Company may be affected by risks regarding the future value of the investment shares. The Company manages securities price risk by setting investment limits and diversifying its investment portfolio.

The Board of Directors assesses that the impact of stock price fluctuations on the Company's profit after tax and equity is insignificant.

Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or transaction contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and other financial instruments.

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

Accounts receivable

The Company regularly monitors its outstanding receivables. For major customers, the Company reviews each customer for deterioration in credit quality at the reporting date. The Company seeks to maintain close control over outstanding receivables and has a credit control staff to minimize credit risk. Based on this and the fact that the Company's trade receivables relate to a large number of different customers, there is no significant concentration of credit risk.

Bank deposit

The Company mainly maintains its deposits with well-known banks in Vietnam. Credit risk from deposits with banks is managed by the Company's treasury department in accordance with the Company's policy. The Company's maximum exposure to credit risk for items on the balance sheet at the end of the reporting period is the carrying amount as disclosed in Note 5.1. The Company considers that the concentration of credit risk in respect of bank deposits is low.

Liquidity risk

Liquidity risk is the risk that the Company will have difficulty in fulfilling its financial obligations due to lack of capital. The Company's liquidity risk arises mainly from the fact that financial assets and financial liabilities have different maturities.

The Company minimizes liquidity risk by maintaining a level of cash and cash equivalents and bank borrowings that the Board of Directors believes is adequate to finance the Company's operations and minimize the risk due to fluctuations in cash flows.

The Company believes that the concentration of risk with respect to debt repayment is low. The Company has adequate access to the necessary sources of funding.

Fair value

The fair value of financial assets and financial liabilities is reflected at the amount at which the financial instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The Company uses the following methods and assumptions to estimate fair value for presentation purposes in the Consolidated Financial Statements:

- The fair value of cash and demand deposits, trade payables, accrued expenses and other payables is equivalent to the carrying amount of these items because these instruments have short-term maturities.
- The fair value of trade receivables and other receivables is assessed by the Company based on information on the repayment of each customer and debtor. Based on this assessment, the Company estimates the provision for the expected uncollectible portion of these receivables. At the end of the accounting period, the Company assesses that the carrying amount of receivables after deducting the provision is not significantly different from the fair value.
- listed securities is determined based on published prices at the reporting date.
- Fair value of unlisted securities, financial investments whose fair price cannot be determined with certainty due to the lack of a liquid market for the securities, financial investments are presented at book value.

Bank loans whose fair value cannot be determined reliably because there is no liquid market for bank loans are stated at carrying amount.

AMERICAN VIETNAMESE BIOTECH INC

4F Phu Ma Duong Building , No. 85 Hoang Van Thai , Tan My Ward, Ho Chi Minh City

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Quarter II 2026

8. OTHER INFORMATION

8.1 Business with stakeholders

The income of key management members during the accounting period is as follows:

Income of the Board of Directors and Board of Director:	This quarter this year VND	This quarter last year VND
Mrs. Dang Nhi Nuong	60,000,000	60,000,000

8.2 Comparatle figures

The comparatle figures on the Consolidated Balance Sheet and corresponding notes are the figures of the Consolidated Financial Statements for the fiscal year ended December 31, 2025

.The figures on the Income Statement, Cash Flow Statement and corresponding notes are the figures of the Company's Consolidated Financial Statements.

8.3 Information on ongoing operations

There are no significant events that could cast significant doubt on the Company's ability to continue as a going concern and the Company has no intention or need to cease operations or reduce the scale of its operations.


8.4 Events occurring after the balance sheet date

The Board of Directors of the Company affirms that, in the opinion of the Board of Directors, in all material respects, there have been no unusual events occurring after the balance sheet date that would affect the financial situation and operations of the Company that require adjustment or presentation in this interim financial report.



Dang Nhi Nuong
Director

Ho Chi Minh City July 30, 2026


Nguyen Thu Huyen
Chief Accountant


Tran Hang Nga
The chartist

